Fayez Sarofim & Co’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$159M Sell
651,329
-7,727
-1% -$1.8M 0.41% 53
2025
Q4
$136M Sell
659,056
-177,924
-21% -$35.2M 0.33% 58
2025
Q3
$155M Sell
836,980
-5,811
-0.7% -$996K 0.36% 60
2025
Q2
$129M Sell
842,791
-35,895
-4% -$5.52M 0.31% 66
2025
Q1
$146M Sell
878,686
-24,804
-3% -$3.88M 0.36% 65
2024
Q4
$131M Buy
903,490
+425
+0% +$65.9K 0.32% 65
2024
Q3
$146M Sell
903,065
-3,779
-0.4% -$602K 0.37% 63
2024
Q2
$133M Sell
906,844
-68,052
-7% -$10.1M 0.36% 61
2024
Q1
$154M Sell
974,896
-63,358
-6% -$10.1M 0.46% 53
2023
Q4
$163M Sell
1,038,254
-257,154
-20% -$39.4M 0.5% 52
2023
Q3
$202M Sell
1,295,408
-406,745
-24% -$67.1M 0.68% 43
2023
Q2
$282M Sell
1,702,153
-334,115
-16% -$53.9M 0.99% 30
2023
Q1
$316M Sell
2,036,268
-348,190
-15% -$56.2M 1.1% 31
2022
Q4
$421M Sell
2,384,458
-23,397
-1% -$4.04M 1.56% 23
2022
Q3
$393M Buy
2,407,855
+2,433
+0.1% +$412K 1.55% 24
2022
Q2
$427M Buy
2,405,422
+152,427
+7% +$27.2M 1.56% 24
2022
Q1
$399M Buy
2,252,995
+136,734
+6% +$23.3M 1.26% 26
2021
Q4
$362M Buy
2,116,261
+61,161
+3% +$10M 1.09% 31
2021
Q3
$332M Sell
2,055,100
-9,045
-0.4% -$1.54M 1.1% 30
2021
Q2
$340M Sell
2,064,145
-13,982
-0.7% -$2.31M 1.14% 30
2021
Q1
$342M Sell
2,078,127
-21,552
-1% -$3.49M 1.26% 29
2020
Q4
$330M Sell
2,099,679
-17,656
-0.8% -$2.61M 1.27% 29
2020
Q3
$315M Sell
2,117,335
-9,530
-0.4% -$1.41M 1.35% 26
2020
Q2
$299M Buy
2,126,865
+153,792
+8% +$22.4M 1.38% 29
2020
Q1
$259M Sell
1,973,073
-110,949
-5% -$15.7M 1.59% 21
2019
Q4
$304M Buy
2,084,022
+1,128
+0.1% +$153K 1.46% 26
2019
Q3
$269M Buy
2,082,894
+3,383
+0.2% +$446K 1.39% 27
2019
Q2
$290M Sell
2,079,511
-93,874
-4% -$13M 1.5% 25
2019
Q1
$304M Buy
2,173,385
+27,659
+1% +$3.7M 1.6% 21
2018
Q4
$277M Sell
2,145,726
-13,640
-0.6% -$1.9M 1.67% 18
2018
Q3
$298M Buy
2,159,366
+14,121
+0.7% +$1.88M 1.56% 18
2018
Q2
$260M Sell
2,145,245
-33,602
-2% -$4.19M 1.4% 25
2018
Q1
$279M Sell
2,178,847
-6,796
-0.3% -$919K 1.51% 22
2017
Q4
$305M Sell
2,185,643
-11,428
-0.5% -$1.59M 1.58% 19
2017
Q3
$286M Sell
2,197,071
-6,543
-0.3% -$867K 1.5% 21
2017
Q2
$292M Sell
2,203,614
-9,211
-0.4% -$1.18M 1.56% 18
2017
Q1
$276M Sell
2,212,825
-77,152
-3% -$9.22M 1.5% 20
2016
Q4
$264M Sell
2,289,977
-56,257
-2% -$6.5M 1.45% 21
2016
Q3
$277M Sell
2,346,234
-49,909
-2% -$6.05M 1.51% 20
2016
Q2
$291M Buy
2,396,143
+130,611
+6% +$14.8M 1.59% 18
2016
Q1
$245M Sell
2,265,532
-77,339
-3% -$8.01M 1.41% 22
2015
Q4
$241M Sell
2,342,871
-151,721
-6% -$15.3M 1.39% 20
2015
Q3
$233M Sell
2,494,592
-1,149,919
-32% -$111M 1.34% 20
2015
Q2
$355M Sell
3,644,511
-361,294
-9% -$36.2M 1.81% 12
2015
Q1
$403M Sell
4,005,805
-1,039,104
-21% -$106M 1.97% 11
2014
Q4
$528M Sell
5,044,909
-524,495
-9% -$55.3M 2.5% 11
2014
Q3
$592M Sell
5,569,404
-133,895
-2% -$13.9M 2.77% 10
2014
Q2
$597M Sell
5,703,299
-178,728
-3% -$18.1M 2.73% 10
2014
Q1
$578M Sell
5,882,027
-167,188
-3% -$15.5M 2.75% 9
2013
Q4
$554M Buy
+6,049,215
New +$557M 2.57% 9
2013
Q2
$556M Buy
+6,472,847
New +$549M 2.79% 8

Other funds holding JNJ

Fayez Sarofim & Co's JNJ Position: Q1 2026 in Review

Fayez Sarofim & Co reduced its Johnson & Johnson (JNJ) stake by 1.2% in Q1 2026, selling an estimated $1.8M and leaving 651,329 shares worth $159M. The position accounts for 0.41% of the portfolio, ranked #53.

Fayez Sarofim & Co first reported a position in JNJ in Q2 2013 and has held it in 51 quarters since. The position peaked at $597M in Q2 2014. 4,618 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Fayez Sarofim & Co held 651,329 shares of Johnson & Johnson worth $159M as of Q1 2026.
  • Fayez Sarofim & Co sold 7,727 Johnson & Johnson shares in Q1 2026, an estimated $1.8M.
  • Johnson & Johnson made up 0.41% of Fayez Sarofim & Co's portfolio in Q1 2026, its #53 holding.
  • Fayez Sarofim & Co first reported a position in Johnson & Johnson in Q2 2013 and has held it in 51 quarters since.
  • Fayez Sarofim & Co's Johnson & Johnson position peaked at $597M in Q2 2014.
  • 4,618 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.